| Segment Reporting Disclosure [Text Block] |
In accordance with ASC 280, “Segment Reporting”, the Company defines an operating segment as a business activity:
|
●
|
from which we may earn revenue and incur expenses;
|
|
●
|
whose operating results are regularly reviewed by the Chief Operating Officer to make decisions about resources to be allocated to the segment and assess its performance; and
|
|
●
|
for which discrete financial information is available.
|
The Company currently has two reporting segments, which are based on a service offering approach. This however, excludes corporate headquarters, which does not generate revenue, our discontinued operations, which includes all facilities as discussed in “Note 4 – Divestiture and Discontinued Operations and Divestitures”, and PF Medical S.A., a developmental entity whose primary purpose at this time is the research and development and marketing of medical isotope technology used in medical diagnostic testing (which is not generating any revenues).
Our reporting segments are defined as follows:
TREATMENT SEGMENT, which includes:
|
|
-
|
nuclear, low-level radioactive, mixed waste (containing both hazardous and low-level radioactive constituents), hazardous and non-hazardous waste treatment, processing and disposal services primarily through four uniquely licensed and permitted treatment and storage facilities; and
|
|
|
-
|
research and development activities to identify, develop and implement innovative waste processing techniques for problematic waste streams.
|
SERVICES SEGMENT, which includes:
|
|
-
|
On-site waste management services to commercial and government customers;
|
|
|
-
|
Technical services, which include:
|
|
|
o
|
professional radiological measurement and site survey of large government and commercial installations using advance methods, technology and engineering;
|
|
|
o
|
integrated Occupational Safety and Health services including industrial hygiene (“IH”) assessments; hazardous materials surveys, e.g., exposure monitoring; lead and asbestos management/abatement oversight; indoor air quality evaluations; health risk and exposure assessments; health & safety plan/program development, compliance auditing and training services; and Occupational Safety and Health Administration (“OSHA”) citation assistance;
|
|
|
o
|
global technical services providing consulting, engineering, project management, waste management, environmental, and decontamination and decommissioning field, technical, and management personnel and services to commercial and government customers; and
|
|
|
o
|
augmented engineering services (through our Schreiber, Yonley & Associates, Inc. subsidiary (“SYA”) – which was divested July 29, 2014) providing consulting environmental services to industrial and government customers:
|
|
|
■
|
including air, water, and hazardous waste permitting, air, soil and water sampling, compliance reporting, emission reduction strategies, compliance auditing, and various compliance and training activities; and
|
|
|
■
|
engineering and compliance support to other segments;
|
|
|
-
|
Nuclear services, which include:
|
|
|
o
|
technology-based services including engineering, decontamination and decommissioning (“D&D”), specialty services and construction, logistics, transportation, processing and disposal;
|
|
|
o
|
remediation of nuclear licensed and federal facilities and the remediation cleanup of nuclear legacy sites. Such services capability includes: project investigation; radiological engineering; partial and total plant D&D; facility decontamination, dismantling, demolition, and planning; site restoration; site construction; logistics; transportation; and emergency response; and
|
|
|
-
|
A company owned equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources (i.e., rental) of health physics, IH and customized nuclear, environmental, and occupational safety and health (“NEOSH”) instrumentation.
|
The table below presents certain financial information of our operating segments as of and for the three and nine months ended September 30, 2014 and 2013 (in thousands).
|
Segment Reporting for the Quarter Ended September 30, 2014
|
|
|
|
|
Treatment
|
|
|
Services
|
|
|
Segments
Total
|
|
|
Corporate (1)
|
|
|
PF Medical
S.A. (1)
|
|
|
Consolidated
Total
|
|
|
Revenue from external customers
|
|
$
|
12,705
|
|
|
$
|
4,200
|
|
|
$
|
16,905
|
|
|
$
|
—
|
|
|
|
—
|
|
|
$
|
16,905
|
|
|
Intercompany revenues
|
|
|
—
|
|
|
|
19
|
|
|
|
19
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
Gross profit
|
|
|
4,943
|
|
|
|
638
|
|
|
|
5,581
|
|
|
|
—
|
|
|
|
—
|
|
|
|
5,581
|
|
|
Interest income
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
7
|
|
|
|
—
|
|
|
|
7
|
|
|
Interest expense
|
|
|
(10
|
)
|
|
|
—
|
|
|
|
(10
|
)
|
|
|
(128
|
)
|
|
|
—
|
|
|
|
(138
|
)
|
|
Interest expense-financing fees
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(52
|
)
|
|
|
—
|
|
|
|
(52
|
)
|
|
Depreciation and amortization
|
|
|
748
|
|
|
|
213
|
|
|
|
961
|
|
|
|
12
|
|
|
|
—
|
|
|
|
973
|
|
|
Segment profit (loss)
|
|
|
3,985
|
|
|
|
10
|
|
|
|
3,995
|
|
|
|
(1,422
|
)
|
|
|
(229
|
)
|
|
|
2,344
|
|
|
Expenditures for segment assets
|
|
|
3
|
|
|
|
39
|
|
|
|
42
|
|
|
|
—
|
|
|
|
—
|
|
|
|
42
|
|
|
Segment Reporting for the Quarter Ended September 30, 2013
|
|
|
|
|
Treatment
|
|
|
Services
|
|
|
Segments
Total
|
|
|
Corporate (1)
|
|
|
PF Medical
S.A. (1)
|
|
|
Consolidated
Total
|
|
|
Revenue from external customers
|
|
$
|
8,929
|
|
|
$
|
10,143
|
|
|
$
|
19,072
|
|
|
$
|
—
|
|
|
|
—
|
|
|
$
|
19,072
|
|
|
Intercompany revenues
|
|
|
82
|
|
|
|
11
|
|
|
|
93
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
Gross profit
|
|
|
1,801
|
|
|
|
1,328
|
|
|
|
3,129
|
|
|
|
—
|
|
|
|
—
|
|
|
|
3,129
|
|
|
Interest income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
8
|
|
|
|
—
|
|
|
|
8
|
|
|
Interest expense
|
|
|
(10
|
)
|
|
|
(1
|
)
|
|
|
(11
|
)
|
|
|
(241
|
)
|
|
|
—
|
|
|
|
(252
|
)
|
|
Interest expense-financing fees
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(40
|
)
|
|
|
—
|
|
|
|
(40
|
)
|
|
Depreciation and amortization
|
|
|
999
|
|
|
|
248
|
|
|
|
1,247
|
|
|
|
20
|
|
|
|
—
|
|
|
|
1,267
|
|
|
Segment profit (loss)
|
|
|
616
|
|
|
|
387
|
|
|
|
1,003
|
|
|
|
(1,571
|
)
|
|
|
—
|
|
|
|
(568
|
)
|
|
Expenditures for segment assets
|
|
|
192
|
|
|
|
6
|
|
|
|
198
|
|
|
|
—
|
|
|
|
—
|
|
|
|
198
|
|
|
Segment Reporting for the Nine Months Ended September 30, 2014
|
|
|
|
|
Treatment
|
|
|
Services
|
|
|
Segments
Total
|
|
|
Corporate (1)
|
|
|
PF Medical
S.A. (1)
|
|
|
Consolidated
Total
|
|
|
Revenue from external customers
|
|
$
|
29,773
|
|
|
$
|
10,333
|
|
|
$
|
40,106
|
|
|
$
|
—
|
|
|
|
—
|
|
|
$
|
40,106
|
|
|
Intercompany revenues
|
|
|
—
|
|
|
|
64
|
|
|
|
64
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
Gross profit
|
|
|
6,379
|
|
|
|
853
|
|
|
|
7,232
|
|
|
|
—
|
|
|
|
—
|
|
|
|
7,232
|
|
|
Interest income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
20
|
|
|
|
—
|
|
|
|
20
|
|
|
Interest expense
|
|
|
(35
|
)
|
|
|
(1
|
)
|
|
|
(36
|
)
|
|
|
(469
|
)
|
|
|
—
|
|
|
|
(505
|
)
|
|
Interest expense-financing fees
|
|
|
—
|
|
|
|
2
|
|
|
|
2
|
|
|
|
(135
|
)
|
|
|
—
|
|
|
|
(133
|
)
|
|
Depreciation and amortization
|
|
|
2,535
|
|
|
|
709
|
|
|
|
3,244
|
|
|
|
38
|
|
|
|
—
|
|
|
|
3,282
|
|
|
Segment profit (loss)
|
|
|
2,977
|
|
|
|
(1,981
|
)
|
|
|
996
|
|
|
|
(4,302
|
)
|
|
|
(414
|
)
|
|
|
(3,720
|
)
|
|
Expenditures for segment assets
|
|
|
334
|
|
|
|
41
|
|
|
|
375
|
|
|
|
—
|
|
|
|
—
|
|
|
|
375
|
|
|
Segment Reporting for the Nine Months Ended September 30, 2013
|
|
|
|
|
Treatment
|
|
|
Services
|
|
|
Segments
Total
|
|
|
Corporate (1)
|
|
|
PF Medical
S.A. (1)
|
|
|
Consolidated
Total
|
|
|
Revenue from external customers
|
|
$
|
26,379
|
|
|
$
|
35,306
|
|
|
$
|
61,685
|
|
|
$
|
—
|
|
|
|
—
|
|
|
$
|
61,685
|
|
|
Intercompany revenues
|
|
|
1,149
|
|
|
|
66
|
|
|
|
1,215
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
Gross profit
|
|
|
3,968
|
|
|
|
3,722
|
|
|
|
7,690
|
|
|
|
—
|
|
|
|
—
|
|
|
|
7,690
|
|
|
Interest income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
27
|
|
|
|
—
|
|
|
|
27
|
|
|
Interest expense
|
|
|
(38
|
)
|
|
|
3
|
|
|
|
(35
|
)
|
|
|
(562
|
)
|
|
|
—
|
|
|
|
(597
|
)
|
|
Interest expense-financing fees
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(87
|
)
|
|
|
—
|
|
|
|
(87
|
)
|
|
Depreciation and amortization
|
|
|
3,063
|
|
|
|
708
|
|
|
|
3,771
|
|
|
|
72
|
|
|
|
—
|
|
|
|
3,843
|
|
|
Segment profit (loss)
|
|
|
524
|
|
|
|
(432
|
)
|
|
|
92
|
|
|
|
(4,528
|
)
|
|
|
—
|
|
|
|
(4,436
|
)
|
|
Expenditures for segment assets
|
|
|
367
|
|
|
|
6
|
|
|
|
373
|
|
|
|
—
|
|
|
|
—
|
|
|
|
373
|
|
(1)Amounts reflect the activity for corporate headquarters and PF Medical S.A. not included in the segment information.
|